Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FAYZ A HUDEFI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Addiction Medicine

NPI
1992740393
CMS profile
135740
Location
FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$124.97

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $124.97 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $124.97 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FAYZ A HUDEFI

NPI 1992740393 · CMS profile ID 135740

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Addiction Medicine

FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $124.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $124.9711/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184963715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $346.37 4
PY2020 $203.40 6
PY2021 $241.28 6
PY2023 $34.77 2
PY2024 $1,099.97 3
PY2025 $124.97 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,184,915.74 413
PY2024 Principal investigator $2,303,282.98 204
PY2023 Principal investigator $6,541,371.44 120
PY2022 Principal investigator $34,086.76 8
PY2021 Principal investigator $312,565.61 85
PY2020 Recipient $1,312.46 7
PY2020 Principal investigator $543,799.24 155
PY2019 Recipient $2,502.81 13
PY2019 Principal investigator $1,252,649.46 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

204 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,761.92 12/18/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238844
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149803
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149807
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149811
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149815
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149818
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,622.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149822
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149826
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149830
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149834
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149837
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,102.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149841
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149845
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149849
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149852
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149856
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149860
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149864
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149868
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149871
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149875
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149879
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149883
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149886
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,622.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149890
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,240.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149894
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149898
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149902
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149906
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149910
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,102.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149914
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,240.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149918
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,886.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149922
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $94.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149926
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $46.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149930
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $42.00 12/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143149934
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,006.24 11/19/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238846
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,330.16 11/12/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238840
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68,462.80 11/12/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238894
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,600.00 11/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238872
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $29,900.00 11/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238874
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,800.00 11/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238876
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,550.00 11/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238884
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,950.00 11/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238886
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143139732
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,460.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141069
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,460.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141073
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141077
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141081
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141084
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141088
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141092
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141095
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,460.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141099
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141103
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141107
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141111
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141114
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141118
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141122
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,460.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141126
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141129
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141133
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141137
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141141
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141148
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,460.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141152
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141155
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141159
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141163
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141167
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141171
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141174
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $94.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141178
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $42.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141182
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,741.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141186
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141190
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,243.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141193
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141197
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141201
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141205
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141209
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,102.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141212
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141216
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141220
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141224
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141228
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141231
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141235
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,240.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141239
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141242
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $59.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141246
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $94.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141250
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $126.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141254
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141257
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $42.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141261
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,741.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141265
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141269
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,243.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141272
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141276
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141280
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141284
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,102.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141288
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141292
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141296
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141300
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141304
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141308
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141312
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,240.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141316
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141320
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141323
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141327
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141331
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141335
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141339
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $59.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141342
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $94.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141346
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $126.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141350
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141354
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $42.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141358
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,741.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141362
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141366
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,243.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141370
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $59.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141374
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $94.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141378
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $42.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141382
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,741.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141385
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141526
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143141865
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142135
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,102.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142515
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142601
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142642
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142660
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142706
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142816
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142853
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $94.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142872
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $126.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142880
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $46.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142886
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143142986
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,968.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143143198
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $42.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143143262
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,243.00 11/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143143623
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,324.48 10/30/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238848
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $512.40 10/15/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238842
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,500.00 10/11/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143139085
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,696.32 10/08/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238836
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $512.40 10/08/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238838
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $512.40 09/24/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238776
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 09/18/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1143133089
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,646.72 09/18/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238770
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,159.12 09/10/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238766
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $512.40 09/03/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238762
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,081.44 08/27/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238778
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,024.80 08/19/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238772
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,252.00 08/13/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238768
Principal investigator 1 Alkermes, Inc. $1,000.00 08/01/2024 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder No dispute reported 06/30/2026 1084813952
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,159.12 08/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238780
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,155.84 07/23/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238774
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,952.08 07/10/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238764
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,728.16 07/02/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238760
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,593.04 06/25/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238724
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,080.16 06/18/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238688
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,752.72 06/11/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238660
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,595.76 05/28/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238730
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $23,577.12 05/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238696
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,271.84 05/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238698
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,820.24 05/14/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238670
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,800.00 05/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125955
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $512.40 05/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238632
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,080.40 04/23/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238704
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,562.56 04/16/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238678
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,593.84 04/12/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238666
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,285.76 04/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238644
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,186.40 04/04/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238646
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $23,726.64 03/26/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238554
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $57,500.00 03/26/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238588
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,000.00 03/21/2024 Non-covered Recipient Entity
Pillar Clinical Research, Llc
An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1123479209
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $28,050.00 03/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238618
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,600.00 03/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238620
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,000.00 03/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238622
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,900.00 03/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238624
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,600.00 03/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238904
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,586.80 03/19/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238548
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,950.16 03/12/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238542
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40,012.00 03/07/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238538
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,179.36 02/29/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238556
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,243.52 02/21/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238550
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,507.84 02/13/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238544
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $39,364.64 02/07/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238536
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $301,300.00 02/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238608
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $50,568.56 01/31/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238558
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,042.75 01/29/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression No dispute reported 06/30/2026 1089696797
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,522.48 01/23/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238552
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,975.92 01/16/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238546
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $276,000.00 01/11/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238616
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $46,388.72 01/09/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238540
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $73,922.24 01/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238534
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $89,700.00 01/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238610
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $154,100.00 01/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238612
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $82,800.00 01/05/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238614
Principal investigator 1 Novartis Pharmaceuticals Corporation $179.31 01/01/2024 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression No dispute reported 06/30/2026 1089690997